This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Octreotide in the treatment of oesophageal varices

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

  • synthetic analogue of somatostatin

  • longer half-life than somatostatin - therefore can be given by bolus injection rather than continuous infusion

  • a meta-analysis has collated trials published in English in which somatostatin or octreotide were compared with other vasoactive drugs (vasopressin or terlipressin), slerotherapy or balloon tamponade - the pooled results showed that somatostatin and octreotide were more effective than the other vasoactive drugs in the initial control of acute bleeding but neither appeared to reduce mortality rates (1)

  • evidence shows that the combination of somatostatin or octreotide and endoscopic therapy is more effective than either alone in controlling an initial oesophageal variceal bleed (2)

Reference:

  • 1) Gotzsche PC. Somatostatin or octreotide for acute bleeding oesophageal varices (Cochrane Review). In: The Cochrane Library, Issue 2, 2000. Oxford: Update Software.
  • 2) Drug and Therapeutics Bulletin (2000), 38 (5), 37-40.

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.